Metabolic Syndrome as a Cardiovascular Disease Risk Factor: Patients Evaluated in Primary Care

Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001, 24: 683-689. 10.2337/diacare.24.4.683.

Reaven GM: Role of insulin resistance in human disease. Diabetes. 1988, 37: 1595-1607. 10.2337/diabetes.37.12.1595.

Rupp H: Insulin resistance, hyperinsulinaemia, and cardiovascular disease. The need for novel dietary prevention strategies. Basic Res Cardiol. 1992, 87: 99-105. 10.1007/BF00801957.

McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, et al: Diagnosing insulin resistance in the general population. Diabetes Care. 2001, 24: 460-464. 10.2337/diacare.24.3.460.

Gerstein HC, Anand S, Yi QL, Vuksan V, Lonn E, Teo K, et al: The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study. Diabetes Care. 2003, 26: 144-149. 10.2337/diacare.26.1.144.

Costa B, Cabré JJ, Martín F: Metabolic syndrome, insulin resistance and diabetes. What is hidden beneath the tip of the iceberg?. Aten Primaria. 2003, 31: 436-445. 10.1157/13046946.

Alberti KGMM, Zimmet PZ, for the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med. 1998, 15: 539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.

Executive Summary of the Third report of the National Cholesterol Education Program (NCEP): Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.

Grundy SM, Cleeman JL, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al: American Heart Association. National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112: 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.

Serrano M, Ascaso JF, Blázquez E, Cabezas J, Cármena R, Escobar F, et al: Grupo de Trabajo Resistencia a la insulina de la Sociedad Española de Diabetes. Insulin resistance and its involvement in multiple risk factors associated with type 2 diabetes mellitus. Med Clin (Barc). 2002, 119: 458-463.

Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, for The European Group for the Study of Insulin Resistance (EGIR), et al: Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002, 28: 364-376.

Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. JAMA. 2002, 287: 356-359. 10.1001/jama.287.3.356.

Reaven GM: Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002, 106: 286-288. 10.1161/01.CIR.0000019884.36724.D9.

Kahn R, Buse J, Ferrannini E, Stern M: American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005, 28: 2289-2304. 10.2337/diacare.28.9.2289.

Albert KGMM, Zimmet P, Shaw J: The metabolic syndrome: a new worldwide definition. The Lancet. 2005, 366: 1059-1062. 10.1016/S0140-6736(05)67402-8.

Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004, 110: 1245-1250. 10.1161/01.CIR.0000140677.20606.0E.

McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care. 2005, 28: 385-390. 10.2337/diacare.28.2.385.

Sattar N, Gaw A, Scherbakova O, Ford I, Lowe GD, O'Reilly DS, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention study. Circulation. 2003, 108: 414-419. 10.1161/01.CIR.0000080897.52664.94.

Alexander CM, Landsman PB, Teutsch SM, Haffner SM: Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003, 52: 1210-1214. 10.2337/diabetes.52.5.1210.

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002, 288: 2709-2716. 10.1001/jama.288.21.2709.

Wannamethee SG, Shaper AG, Lennon L, Morris RW: Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005, 165: 2644-2650. 10.1001/archinte.165.22.2644.

Rigo F, Frontera J, Llobera J, Rodríguez T, Borrás I, Fuentespina E: Prevalence of cardiovascular risk factors in the Balearic Islands (CORSAIB Study). Rev Esp Cardiol. 2005, 58: 1411-1419. 10.1016/S1885-5857(06)60748-2.

Anonymous: Prevention of coronary heart disease in clinical practice-Summary of recommendations. Rev Esp Cardiol. 2000, 53: 412-421.

Alvarez LA, Suárez C, Mantilla T, Franch J, Ruilope LM, Banegas JR, et al: PREVENCAT Study: control of cardiovascular risk in primary care. Med Clin (Barc). 2006, 124: 406-410. 10.1157/13072841.

Tomás L, Varas C, Pérez I, Puig T, Balaguer I: Risk factors and coronary morbimortality in a Mediterranean industrial cohort over 28 years of follow-up. The Manresa Study. Rev Esp Cardiol. 2001, 54: 1146-1154.

González JR, Alegría E, Lozano JV, Llisterri JL, García JM, González I: Impact of hypertension in cardiac diseases in Spain. The CARDIOTENS Study 1999. Rev Esp Cardiol. 2001, 54: 139-149. 10.1157/03008932054000220010139.

Pineda M, Custardoy J, Andreu MT, Ortín JM, Cano JG, et al: Grupo de Investigación Clínica del Sureste (GICS). Prevalence study of cardiovascular risk factors in a health area. Aten Primaria. 2002, 30: 207-213.

Alegría E, Cordero A, Laclaustra M, Grima A, León M, Casasnovas JA, et al: Prevalence of metabolic syndrome in the Spanish working population. MESYAS registry. Rev Esp Cardiol. 2005, 58: 797-806. 10.1157/13077231.

Anderson KM, Wilson PWF, Odell PM, Kanell WB, Framingham : An update coronary risk profile. A statement for health professionals. Circulation. 1991, 83: 356-362.

Marrugat J, Solanas P, D'Agostino R, Sulllivan L, Ordovás J, Cordón F, Kannel WB, et al: Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol. 2003, 56: 253-261. 10.1157/13043951.

Marrugat J, Vila J, Pevesi P, Sanz F: Estimation of the sample size in clinical and epidemiological investigations. Med Clin (Barc). 1998, 111: 267-276.

IDF: The IDF consensus worldwide definition of the metabolic syndrome. Berlin. 14 April 2005. [consulted 15/08/07], [ http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf ]

Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS: Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004, 109: 42-46. 10.1161/01.CIR.0000108926.04022.0C.

Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004, 27: 2444-2449. 10.2337/diacare.27.10.2444.

Wang J, Li HB, Kinnunen L, Hu G, Jarvinen TM, Miettinen ME, Yuan S, Tuomilehto J: How well does the metabolic syndrome defined by five definitions predict incident diabetes and incident coronary heart disease in a Chinese population?. Atherosclerosis. 2007, 192: 161-168. 10.1016/j.atherosclerosis.2006.04.027.

Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J: The metabolic syndrome predicts incident stroke. A 14-year follow-up study in elderly people in Finland. Stroke. 2008, 39: 1078-1083. 10.1161/STROKEAHA.107.499830.

Moebus S, Hanisch JU, Aidelsburger P, Bramlage P, Wasem J, Jöckel KH: Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovascular Diabetology. 2007, 6: 22-10.1186/1475-2840-6-22. doi:10.1188/1475-2840-6-22

Athyros VG, Bouloukos VI, Pehlivanidis AN, Papageorgiou AA, Dionysopoulou SG, Symeonoidis AN, et al: The prevalence of the metabolic syndrome in Greece: The MetS-Greece Multicentre Study. Diabetes, Obesity and Metabolism. 2005, 7: 397-405. 10.1111/j.1463-1326.2004.00409.x.

Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al: Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007, 49: 40-47. 10.1161/01.HYP.0000251933.22091.24.

Lawlor DA, Smith GD, Ebraihm S: Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia. 2006, 49: 41-48. 10.1007/s00125-005-0040-3.